lactoquinomycin A: effective against Ehrlich carcinoma in mice; isolated from Streptomyces tanashiensis; MF: C24-H27-N-O8; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124692 |
| SCHEMBL ID | 13142438 |
| MeSH ID | M0136736 |
| Synonym |
|---|
| from streptomyces tanashiensis |
| nsc607171 |
| lactoquinomycin a, hydrochloride |
| lactoquinomycin a |
| 2h-furo(3,2-b)naphtho(2,3-d)pyran-2,6,11-trione, 3,3a,5,11b-tetrahydro-7-hydroxy-5-methyl-8-(2,3,6-trideoxy-3-(dimethylamino)-beta-arabino-hexopyranosyl)-, (3a-alpha,5-alpha,11b-alpha)-(+)- |
| [4-(dimethylamino)-5-hydroxy-6-methyl-tetrahydropyran-2-yl]-hydroxy-methyl-[?]trione |
| lactoquinomycin |
| 100100-36-5 |
| SCHEMBL13142438 |
| DTXSID40905207 |
| 1,5-anhydro-2,3,6-trideoxy-3-(dimethylamino)-1-(7-hydroxy-5-methyl-2,6,11-trioxo-3,3a,5,6,11,11b-hexahydro-2h-furo[3,2-b]naphtho[2,3-d]pyran-8-yl)hexitol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||